{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Manohar M"],"funding":["Simons Foundation","NIAID NIH HHS","National Institutes of Health","NIH HHS"],"pagination":["2809-2826"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8609920"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["76(9)"],"pubmed_abstract":["<h4>Background</h4>Multifood oral immunotherapy (mOIT) with adjunctive anti-IgE (omalizumab, XOLAIR<sup>®</sup> ) treatment affords safe, effective, and rapid desensitization to multiple foods, although the specific immune mechanisms mediating this desensitization remain to be fully elucidated.<h4>Methods</h4>Participants in our phase 2 mOIT trial (NCT02643862) received omalizumab from baseline to week 16 and mOIT from week 8 to week 36. We compared the immune profile of PBMCs and plasma taken at baseline, week 8, and week 36 using high-dimensional mass cytometry, component-resolved diagnostics, the indirect basophil activation test, and Luminex.<h4>Results</h4>We found (i) decreased frequency of IL-4<sup>+</sup> peanut-reactive CD4<sup>+</sup> T cells and a marked downregulation of GPR15 "],"journal":["Allergy"],"pubmed_title":["Immune changes beyond Th2 pathways during rapid multifood immunotherapy enabled with omalizumab."],"pmcid":["PMC8609920"],"funding_grant_id":["U19AI104209","5UM2AI130836‐04","U19 AI104209","U01 AI140498","R01AI140134-02","T32 AI007512","5T32AI007512","R01AI140134‐02","U01 AI140498-03","U01 AI147462","5UM2AI130836-04","R01 AI140134","U01 AI140498‐03","UM2 AI130836","R01AI119918","R01 AI119918"],"pubmed_authors":["DeKruyff RH","Gupta S","Desai M","Boyd SD","Oettgen HC","Zhang W","Andorf S","Nadeau KC","Roy Chowdhury R","Yan Z","Minnicozzi S","Kost LE","Galli SJ","Manohar M","Maecker HT","Yu W","Kirkey M","Bunning B","Chinthrajah RS","Dunham D"],"additional_accession":[]},"is_claimable":false,"name":"Immune changes beyond Th2 pathways during rapid multifood immunotherapy enabled with omalizumab.","description":"<h4>Background</h4>Multifood oral immunotherapy (mOIT) with adjunctive anti-IgE (omalizumab, XOLAIR<sup>®</sup> ) treatment affords safe, effective, and rapid desensitization to multiple foods, although the specific immune mechanisms mediating this desensitization remain to be fully elucidated.<h4>Methods</h4>Participants in our phase 2 mOIT trial (NCT02643862) received omalizumab from baseline to week 16 and mOIT from week 8 to week 36. We compared the immune profile of PBMCs and plasma taken at baseline, week 8, and week 36 using high-dimensional mass cytometry, component-resolved diagnostics, the indirect basophil activation test, and Luminex.<h4>Results</h4>We found (i) decreased frequency of IL-4<sup>+</sup> peanut-reactive CD4<sup>+</sup> T cells and a marked downregulation of GPR15 ","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Sep","modification":"2026-05-08T01:54:29.503Z","creation":"2024-11-20T11:17:59.577Z"},"accession":"S-EPMC8609920","cross_references":{"pubmed":["33782956"],"doi":["10.1111/all.14833"]}}